about
Positron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response MonitoringLuciferase fragment complementation imaging in preclinical cancer studiesPhosphorylation status of thymidine kinase 1 following antiproliferative drug treatment mediates 3'-deoxy-3'-[18F]-fluorothymidine cellular retentionPreclinical assessment of carboplatin treatment efficacy in lung cancer by 18F-ICMT-11-positron emission tomographyIdentification of ABC Transporter Interaction of a Novel Cyanoquinoline Radiotracer and Implications for Tumour Imaging by Positron Emission TomographyThe anticancer gene ORCTL3 targets stearoyl-CoA desaturase-1 for tumour-specific apoptosisMicrowave gallium-68 radiochemistry for kinetically stable bis(thiosemicarbazone) complexes: structural investigations and cellular uptake under hypoxia.AKT activation controls cell survival in response to HDAC6 inhibition.Evaluation of 18F-fluorothymidine positron emission tomography ([18F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer.Clinical translation of molecular imaging agents used in PET studies of cancer.Fully automatic, multiorgan segmentation in normal whole body magnetic resonance imaging (MRI), using classification forests (CFs), convolutional neural networks (CNNs), and a multi-atlas (MA) approach.Preclinical Applications of 3'-Deoxy-3'-[18F]Fluorothymidine in Oncology - A Systematic Review.Scavenging strategy for specific activity improvement: application to a new CXCR4-specific cyclopentapeptide positron emission tomography tracer.Preclinical evaluation of 3-18F-fluoro-2,2-dimethylpropionic acid as an imaging agent for tumor detection.Radiolabeled RGD tracer kinetics annotates differential αvβ 3 integrin expression linked to cell intrinsic and vessel expression.Evaluation of deuterated 18F- and 11C-labeled choline analogs for cancer detection by positron emission tomography.Design of symmetrical and nonsymmetrical N,N-dimethylaminopyridine derivatives as highly potent choline kinase alpha inhibitorsExploiting altered patterns of choline kinase-alpha expression on human prostate tissue to prognosticate prostate cancer.Erratum to: Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer.Preliminary clinical assessment of the relationship between tumor alphavbeta3 integrin and perfusion in patients studied with [(18)F]fluciclatide kinetics and [ (15)O]H 2O PET.Erratum to: Anti-nicastrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells.Correction to: The relationship between endogenous thymidine concentrations and [18F]FLT uptake in a range of preclinical tumour models.3'-Deoxy-3'-[(18)F]Fluorothymidine Uptake Is Related to Thymidine Phosphorylase Expression in Various Experimental Tumor Models.A multifractal approach to space-filling recovery for PET quantification.Towards an MMP-2-activated molecular agent for cancer imaging.Apparent Diffusion Coefficient of Normal Abdominal Organs and Bone Marrow From Whole-Body DWI at 1.5 T: The Effect of Sex and Age.Mn-salen catalysed benzylic C-H activation for the synthesis of aryl [(18)F]CF3-containing PET probes.The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell deathClinical translation of [F]ICMT-11 for measuring chemotherapy-induced caspase 3/7 activation in breast and lung cancerA mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancerDiscovery of pre-therapy 2-deoxy-2-F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients3D Growth of Cancer Cells Elicits Sensitivity to Kinase Inhibitors but Not Lipid Metabolism ModifiersDevelopment and Evaluation of an F-Radiolabeled Monocyclam Derivative for Imaging CXCR4 ExpressionEfficacy of systemic temozolomide-activated phage-targeted gene therapy in human glioblastomaEvaluation of apoptosis imaging biomarkers in a genetic model of cell deathIodination of terminal alkynes using KI/CuSO4 - A facile method with potential for radio-iodination.Caspase-Based PET for Evaluating Pro-Apoptotic Treatments in a Tuberculosis Mouse ModelRadiological assessment of Peritoneal Cancer Index on preoperative CT in ovarian cancer is related to surgical outcome and survivalFluorescence enhancement from single gold nanostars: towards ultra-bright emission in the first and second near-infrared biological windowsTowards multiplexed near-infrared cellular imaging using gold nanostar arrays with tunable fluorescence enhancement
P50
Q26765882-0926A522-9EAD-4EAB-B9A1-979AD25B5FEEQ26851635-6AA2A808-BCDE-4647-A848-742E2A577D61Q28540476-3FC9DAD9-1F55-4B38-8072-D090063788C9Q28540769-A822E595-65C2-41E7-ABE8-36B804C7332AQ28553692-50A9B87F-4F11-43BC-9582-68A35FCB30AAQ33992032-CEDB34B2-FC9B-46D0-9EAF-41407CA365EAQ35846041-7E40680F-FB1D-4332-B0AD-026BB60CBC7EQ37412534-2F081829-90AE-4E50-9EFA-CBC331CEA088Q37418581-B83B5766-6459-4ED6-89EE-A5A9C94FD8D6Q38257327-7AB335B4-DB6D-469E-AEE8-564DDC6E3CC5Q38653246-F9E7D8EE-F747-48A9-BE45-F8C8E2E4B58CQ38775709-50771C27-EBB0-45BE-AAEB-77C09EE9AAE2Q38959024-22B9B257-9C8F-4408-9BE3-098EE56B748CQ38976550-74A40520-DA7D-42BC-BB7F-7BA9FF1C0056Q39047828-DCABAB27-218E-411B-9471-4B718E44E6A0Q39414054-0A82B932-6D47-4F5F-91A7-4BA310CFB6D9Q41224108-76216855-586F-45F2-BD32-473102B1D693Q41695208-7C034C3B-A4CD-4582-BB55-9BE33C0E6438Q42751410-8FE7EFD0-1389-4B3A-BCB9-CE671FF5ED71Q42754801-CCF6207F-A77C-4BA7-B6EF-D7A3D0168F4EQ45870013-381328D6-426B-4A46-861D-519735D83C50Q47127952-E8F4EA9E-4FC4-4BBC-ACCF-98B9038B0C08Q47877900-7A4422C7-558A-4B01-9F66-68D0B6567DA4Q48813461-0C425BA6-EFEF-42C9-97A1-A20221D9DF7AQ50110755-BB5E3BBC-D036-4545-A197-C5308FC124F5Q50439698-17526DBB-8D1B-4E74-8EDC-20FDC9CEDB39Q53024784-A40EFAB8-B0DE-459F-8D9D-111A9B346AADQ57461609-E7FAC9E4-4C90-4CBF-B958-7C1B917611FBQ59127014-A1B69F98-065C-4270-964A-04C6C21EC8ACQ61795892-D1BD8072-3C76-4003-95BC-D900D9EAE329Q61820904-E3E89983-3827-4CD9-8661-FBCB04180765Q63865774-06593C73-14B5-46D6-8CB4-C085D66F5830Q64081483-FCEFEA30-F115-4786-88F5-20D46D03FE42Q64094581-8A73DFCD-62D8-420C-8D53-A78201651321Q64258576-E7AB2A1B-565B-4EC1-BE88-565B67F00842Q64915375-9638F5B8-2A37-4D67-B6D0-D9721C557746Q90785667-68A06367-2EDE-42CB-A387-5C05F2A890A6Q90839857-233AED52-E1AA-454A-83DB-7F3C35688E5EQ90932419-EC72D80A-209F-4523-ADCD-AA09A72D0AADQ91069549-5E08C24A-8E6B-43A1-B516-487CFE3E66E0
P50
description
researcher (ORCID 0000-0003-2276-6771)
@en
name
Eric O Aboagye
@en
type
label
Eric O Aboagye
@en
prefLabel
Eric O Aboagye
@en
P31
P496
0000-0003-2276-6771